Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Double-blind, Randomized Controlled Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced NSCLC

NCT06276933 is registered in ClinicalTrials.gov with Tongji University as lead sponsor.

NCT NCT06276933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Double-blind, Randomized Controlled Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced NSCLC
Lead sponsor
Tongji University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
February 22, 2024
Completion date
November 22, 2026
Enrollment
104 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

camrelizumab, lung cancer